Current Environment: Production

Munir Mobassaleh | Education

Medical School

American University of Beirut

Beirut, Lebanon

Internship

American University of Beirut

Beirut, Lebanon

Residency

American University of Beirut

Beirut, Lebanon

Residency

Boston University, Boston City Hospital

Boston, MA

Fellowship

Tufts University, New England Medical Center

Boston, MA

Munir Mobassaleh | Certifications

  • American Board of Pediatrics (Gastroenterology)

Munir Mobassaleh | Professional History

At the onset of his career as a Pediatric Gastroenterologist, Dr. Mobassaleh’s focus was on basic research in the field of pathogenesis of Shigella Diarrhea and the developmental regulation of the Shiga toxin receptors.  He was funded through the National Institutes of Health to conduct this research. Dr. Mobassaleh truly enjoyed his time in the laboratory and appreciated the effects of laboratory research on the advancement of human health.  However, with time, he realized that his true interests were in the fields of direct patient care, teaching students, both residents and fellows, and the development of outreach programs.  Dr. Mobassaleh’s current focus is in those areas and he currently holds a particular role in the field of community outreach and community-physician relations.  His goals focus on collaboration with primary care physicians in order to bring subspecialty care plans into the community and allow patients easy and timely access to such care.

Munir Mobassaleh | Publications

  1. Histological esophagitis: clinical and histological response to omeprazole in children. Dig Dis Sci. 1999 Jan; 44(1):134-9. View Histological esophagitis: clinical and histological response to omeprazole in children. Abstract

  2. Developmental delay and growth failure caused by a peroxisomal disorder, dihydroxyacetonephosphate acyltransferase (DHAP-AT) deficiency. Am J Med Genet. 1998 Nov 16; 80(3):223-6. View Developmental delay and growth failure caused by a peroxisomal disorder, dihydroxyacetonephosphate acyltransferase (DHAP-AT) deficiency. Abstract

  3. Proarrhythmia associated with cisapride in children. Pediatrics. 1998 Jun; 101(6):1053-6. View Proarrhythmia associated with cisapride in children. Abstract

  4. Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. J Clin Invest. 1995 Sep; 96(3):1328-35. View Maturational regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. Abstract

  5. Developmentally regulated Gb3 galactosyltransferase and alpha-galactosidase determine Shiga toxin receptors in intestine. Am J Physiol. 1994 Oct; 267(4 Pt 1):G618-24. View Developmentally regulated Gb3 galactosyltransferase and alpha-galactosidase determine Shiga toxin receptors in intestine. Abstract

  6. Pathogenesis of Shigella diarrhea: XVII. A mammalian cell membrane glycolipid, Gb3, is required but not sufficient to confer sensitivity to Shiga toxin. J Infect Dis. 1994 Mar; 169(3):538-46. View Pathogenesis of Shigella diarrhea: XVII. A mammalian cell membrane glycolipid, Gb3, is required but not sufficient to confer sensitivity to Shiga toxin. Abstract

  7. A quantitative immunostaining method for the measurement of UDP-galactose:lactosylceramide galactosyltransferase for the synthesis of globotriaosylceramide in rabbit small intestine and HeLa cells. Anal Biochem. 1993 Oct; 214(1):295-300. View A quantitative immunostaining method for the measurement of UDP-galactose:lactosylceramide galactosyltransferase for the synthesis of globotriaosylceramide in rabbit small intestine and HeLa cells. Abstract

  8. Efficacy of cimetidine for gastric acid suppression in pediatric patients. J Pediatr. 1992 Mar; 120(3):474-8. View Efficacy of cimetidine for gastric acid suppression in pediatric patients. Abstract

  9. Shiga toxin: intestinal cell receptors and pathophysiology of enterotoxic effects. Rev Infect Dis. 1991 Mar-Apr; 13 Suppl 4:S304-10. View Shiga toxin: intestinal cell receptors and pathophysiology of enterotoxic effects. Abstract

  10. Quantitation of the rabbit intestinal glycolipid receptor for Shiga toxin. Further evidence for the developmental regulation of globotriaosylceramide in microvillus membranes. Gastroenterology. 1989 Aug; 97(2):384-91. View Quantitation of the rabbit intestinal glycolipid receptor for Shiga toxin. Further evidence for the developmental regulation of globotriaosylceramide in microvillus membranes. Abstract

  11. Pathogenesis of shigella diarrhea: evidence for a developmentally regulated glycolipid receptor for shigella toxin involved in the fluid secretory response of rabbit small intestine. J Infect Dis. 1988 May; 157(5):1023-31. View Pathogenesis of shigella diarrhea: evidence for a developmentally regulated glycolipid receptor for shigella toxin involved in the fluid secretory response of rabbit small intestine. Abstract

  12. Pathogenesis of Shigella diarrhea: rabbit intestinal cell microvillus membrane binding site for Shigella toxin. Infect Immun. 1986 Aug; 53(2):372-7. View Pathogenesis of Shigella diarrhea: rabbit intestinal cell microvillus membrane binding site for Shigella toxin. Abstract

  13. Development of carbohydrate absorption in the fetus and neonate. Pediatrics. 1985 Jan; 75(1 Pt 2):160-6. View Development of carbohydrate absorption in the fetus and neonate. Abstract

I became interested in the biological sciences at early stage. During my college years, I realized that my true passion was in applying this knowledge into all aspects of patient care, both research and practice. This led me to enter the field of medicine.

My philosophy in practicing medicine is to treat all patients and their families with respect, and empower them to be actively involved in their own care and the process of decision making. My basic principle is to treat patients and families as I would treat my own. This shapes and influences my decisions in patient care.

BESbswy
BESbswy